Serum Bisphenol A is an independent risk factor of hyperuricemia: A 6-year prospective study

This study aims to evaluate whether serum Bisphenol A (BPA) is a risk factor for hyperuricemia.

In this prospective study, a total of 482 participants without hyperuricemia were enrolled at baseline and followed up for 6 years. Clinical characteristics were recorded, and serum levels of uric acid and BPA were measured. Participants were stratified into tertiles according to low, median, and high baseline serum BPA levels. Regression models were used to analyze associations of serum BPA with the change in uric acid and the risk of developing hyperuricemia.

At baseline, serum concentrations of BPA was 0.51 (0.24-2.37) ng/mL. After 6 years of follow-up, the change in serum uric acid concentration from baseline to the 6-year mark was significantly higher in subjects with higher baseline BPA concentration (0.03 ± 0.19, 0.07 ± 0.21, and 0.11 ± 0.25mg/dL for low, median, and high tertiles, respectively, P = 0.006). When adjusted for potential confounders, such as age, renal function, and history of diabetes and hypertension, multivariable logistic analyses showed that subjects in the median or high baseline BPA tertiles exhibited a twofold higher risk of 6-year hyperuricemia incidence compared to subjects in the low baseline BPA tertile [odds ratio (OR) = 2.28 (95% CI: 1.05-4.95) for the median tertile; 2.42 (1.07-5.48) for the high tertile, P_{for Trend} = 0.043].

In conclusion, serum BPA is an independent risk factor for hyperuricemia.